BioSpace News Archive

Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that it will host a virtual Key Opinion Leader (KOL) meeting on oral paltusotine for the treatment of acromegaly on Friday, November 20, 2020 at 11:00 am Eastern Time. The call will feature a presentat

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended September 30, 2020 on November 19, 2020, before the U.S. financial markets open. Entera’s management will host a conference call on Thursday, November 19, 2020 at 8:30 a.m. ET to discuss the results for the quarter. A question-and-answer session will follow

Company Management and Principal Investigator of ReSPECT to Discuss Interim Data Webinar Scheduled for Thursday, November 19, 2020 at 4:30 - 5:30 p.m. ET

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it will be providing an update on its Ifenprodil Phase 2 human clinical studies presented by Christopher J. Moreau, CEO and Dr. Mark Williams, CSO and hosted by Dr. KSS MD PhD. The BioPub webcast will be held Friday, November 13, 2020 at noon

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced its financial results for the first quarter ended September 30, 2020 and provided a corporate update.

Helio Health, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today presented new data that demonstrate the high accuracy and screening value of its cell-free DNA (cfDNA) methylation blood test for the detection of hepatocellular carcinoma (HCC)

Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology, today announced that Pearl Huang, Ph.D., President and Chief Executive Officer, will present a company overview at the 2020 Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 8:40 a.m. E.T.

Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, today announced first-in-human clinical data supporting the safety of Glympse’s biosensors and data from a gene expression study of patients with advanced fibrosis demonstrating the important role of proteases in NASH pathophysiology.

Silverback Therapeutics, Inc. (“Silverback”) (“the Company”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue-targeted therapeutics, will present preclinical data for SBT8230 at AASLD The Liver Meeting Digital Experience (November 13-16, 2020).

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the company’s senior management will participate in the following virtual investor conferences